Table 1.
Incidence of hMPV infections, hMPV-LRTI, and hMPV mortality in HCT recipients and HM patients, n (%).
| Author, year | Study time period |
Location | Age | Number of patients evaluated (Symptomat ic/Asympto matic) |
Type of diagnostic test |
hMPV incidence (hMPV/patient s evaluated) |
hMPV-LRTI (LRTI/ number of hMPV infections) |
hMPV mortality (deaths/ number of hMPV infections) |
hMPV- deaths/hMPV- LRTI |
|---|---|---|---|---|---|---|---|---|---|
| HCT recipients | |||||||||
| Lee 2011[38]a | 2007–2009 | Seoul, Korea | Children | 211 (S) | PCR, culture | 0 | 0 | 0 | 0 |
| Fazekas-A, 2012[39]a | 2007–2009 | Vienna, Austria | Children | 31 (AS) | PCR | 8 (26) | NA | NA | NA |
| Srinivasan-A 2013[40]a | Oct 2010 – Sept 2011 |
Memphis, TN | Children | 42 (S) | PCR | 1 (2) | 1 (100) | NA | NA |
| Choi, 2013[41]a | 2007–2010 | Seoul, Korea | Children | 116 (S) | RT-PCR | 1 (1) | 0 | 0 | 0 |
| Martino, 2005[42]a | 1999–2003 | Barcelona, Spain | Adult | 177 (S) | IF, culture | 16 (9) | 5 (31) | 2 (13) | 2 (40) |
| Debiaggi, 2007[36]a | 2004–2006 | Italy | Adult | 53 (AS) | RT-PCR | 21 (40) | NA | NA | NA |
| Souza 2013[43]b | Mar 2008–Feb 2009 |
Sao Paulo, Brazil | Adult | 75 (S) | PCR | 11 (14.7) | NA | NA | NA |
| Peck, 2007[2]b | 2000–2004 | Seattle, WA | Any | 122 (AS) | Culture, DFA, PCR |
6 (5) | 0 | 0 | - |
| Debur, 2010[44]a | 2000–2002; 2006–2008 |
Curitiba, Brazil | Any | 189 (S) | RT-PCR | 18 (10) | 5 (28) | 0 | 0 |
| Wolfromm, 2011[45]a | 2007–2010 | Paris, France | Any | 127 (S) | PCR | 6 (5) | NA | 1 (17) | NA |
| Oliveira, 2008[46]a | 2001–2003 | Sao Paulo, Brazil | NA | 153 (S) | RT-PCR, IF | 11 (7) | 3 (27) | 1 (9) | 1 (33) |
| Mikulska, 2011[47]a | 2007–2010 | Genoa, Italy | NA | 208 (S) | PCR | 4 (2) | NA | NA | NA |
| HM patients | |||||||||
| Fazekas-B, 2012[39]a | 2007–2009 | Vienna, Austria | Children | 103 (AS) | PCR | 11 (11) | NA | NA | NA |
| Srinivasan-B, 2013[40] a |
Oct 2010 – Sept 2011 |
Memphis, TN | Children | 121 (S) | PCR | 5 (4) | 4 (80) | NA | NA |
| Chebotkevich, 2010[48] a |
2008–2009 | St. Petersburg, Russia | Any | 48 (S) | RT-PCR | 2 (4) | NA | NA | NA |
| HM and HCT patients | |||||||||
| Williams, 2005[1]a | 1999–2004 | Barcelona, Spain | Adult | 128 (S) | RT-PCR | 22 (17) | 9 (41) | 3 (14) | 3 (33) |
| Kwon, 2012 [49]c | Apr 2009– Aug 2011 |
Seoul, Korea | Adult | 176 (AS) | PCR | 1 (0.6) | NA | NA | NA |
| Park, 2013 [50]a | Jan 2009 – Feb 2012 |
Seoul, Korea | Adult | 737 (S) | PCR | 21 (2.8) | NA | NA | NA |
| Kamboj, 2008[17]b | 2005–2007 | NYC, USA | Any | 1211 (S) | DFA, RT-PCR, Shell vial assay |
39 (3) | NA | 0 | NA |
a
Single center investigator-initiated study;
b
samples collected during respiratory seasons;
c
only patients who underwent bronchoscopy
Data from Fazekas et al. (2012)[39] were split for hMPV incidence in the HM and HCT groups, respectively;
DFA = direct fluorescent antibody; hMPV-LRTI indicates human metapneumovirus-associated lower respiratory tract infections; HCT recipient = hematopoietic cell transplant recipients; HM = hematologic malignancy; IF = immunofluorescence; NA= not available; PCR = polymerase chain reaction; RT-PCR = reverse transcription polymerase chain reaction